Venus Remedies Receives Saudi FDA Approval for Plerixafor
Venus Remedies has received Saudi FDA approval for Plerixafor, marking its first global authorization for the specialty oncology drug.
It's time to celebrate another noteworthy achievement for Venus Remedies. We have taken another important step in strengthening our global oncology presence with marketing approval from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This significant regulatory breakthrough represents the company’s first global authorization for the drug, reinforcing our complex injectables in regulated markets.
Addressing Needs in Oncology Care
Plerixafor is a hematopoietic stem cell mobiliser used alongside granulocyte-colony stimulating factor (G-CSF). The drug plays a vital role for patients with multiple myeloma and non-Hodgkin lymphoma by facilitating the movement of stem cells into the bloodstream for collection and transplantation.
With this approval, Venus Remedies is targeting oncology centres and hospitals in Saudi Arabia by commercializing its Plerixafor injection 24 mg/1.2 ml through its established international distribution network.
Commenting on the achievement, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and Venus Medicine Research Centre CEO, said, "This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in". He further added, "Plerixafor sits squarely in the kind of therapy class we are building our international portfolio around. These are speciality injectables where clinical complexity and regulatory rigour create durable demand. It is also a meaningful addition for haemato-oncology centres across Saudi Arabia, where stem cell transplantation volumes are rising."
Strategic Entry into a High-Value Market
With a growing demand for advanced cancer and transplant-related treatments, Saudi Arabia is one of the largest pharmaceutical markets in the Gulf region. The country’s growing need for innovative therapies offers us significant opportunities to develop specialized pharmaceutical products that address unmet clinical needs. Expanding our healthcare infrastructure in the area is serving this need for specialised therapies, enhancing the company’s visibility on the global stage.
Aditi K Chaudhary, President, International Business, Venus Remedies Limited, said, "Saudi Arabia is the most important commercial market in the GCC for speciality oncology, and this approval gives us a direct platform there. We will use it to build hospital partnerships and to anchor further speciality launches across the region. Regulatory and commercial work are tightly linked in markets like this, and the SFDA approval is evidence of both lines of execution working."
A Step Forward Towards Global Growth
The SFDA approval for Plerixafor marks a defining moment in Venus Remedies’ international journey. It enhances our chances of expanding our commercial footprint across the Middle East for the drug. Moreover, this approves the company as a trusted supplier of complex and specialty injectables with expertise in research and regulatory compliance. The milestone represents another step forward in our journey toward becoming a leading global provider of specialty and critical-care pharmaceuticals.
